SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jacobsson Lennart T. H. 1954 )
 

Search: WFRF:(Jacobsson Lennart T. H. 1954 ) > Inflammatory hallma...

  • Hansen, R. L.Copenhagen University Hospital (author)

Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2020-06-27
  • Oxford University Press (OUP),2021

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/302085
  • https://gup.ub.gu.se/publication/302085URI
  • https://doi.org/10.1093/rheumatology/keaa237DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:145746356URI
  • https://lup.lub.lu.se/record/8e8363ae-032f-407c-9d2a-3957f87fbfb5URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objectives. To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries. Methods. PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R-2 calculations and point prevalence of bDMARD treatment. Results. A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association. Conclusion. Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Jorgensen, T. S.Copenhagen University Hospital (author)
  • Dreyer, L.Aalborg University Hospital,Copenhagen University Hospital (author)
  • Hetland, M. L.Copenhagen University Hospital,University of Copenhagen (author)
  • Glintborg, B.Copenhagen University Hospital,University of Copenhagen (author)
  • Askling, J.Karolinska Institute,Karolinska Institutet (author)
  • Di Giuseppe, D.Karolinska Institute,Karolinska Institutet (author)
  • Jacobsson, Lennart T. H.,1954University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy(Swepub:gu)xjacle (author)
  • Wallman, Johan K.Lund University,Lunds universitet,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-jnk (author)
  • Nordstrom, D.Helsinki University Central Hospital (author)
  • Aaltonen, K. (author)
  • Kristianslund, E. K.Diakonhjemmet Hospital (author)
  • Kvien, T. K.Diakonhjemmet Hospital (author)
  • Provan, S. A.Diakonhjemmet Hospital (author)
  • Gudbjornsson, B.National University Hospital of Iceland (author)
  • Love, T. J.University of Iceland (author)
  • Kristensen, L. E.Copenhagen University Hospital (author)
  • Copenhagen University HospitalAalborg University Hospital (creator_code:org_t)

Related titles

  • In:Rheumatology: Oxford University Press (OUP)60:1, s. 140-1461462-03241462-0332

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view